Subscribe to RSS

DOI: 10.1055/a-2780-0387
SAFER: A Programme of Research to Determine if Intermittent Single-Lead ECG Screening for Atrial Fibrillation Reduces the Risk of Stroke
Authors
Funding Information The SAFER programme is funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research (RP-PG-0217-20007). SAFER is a contributor to/partner of AFFECT-EU, receiving funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement number 847770. The NIHR School for Primary Care Research (SPCR-2014-10043, project 410) funded parts of the feasibility study. This work was supported by core funding from the NIHR Cambridge Biomedical Research Centre (NIHR203312).The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the United Kingdom Department of Health and Social Care. Clinical Trial Registration ISRCTN72104369
Abstract
This article describes the SAFER (Screening for Atrial Fibrillation with ECG to Reduce stroke) programme that was established to determine whether intermittent screening for atrial fibrillation with a single-lead electrocardiogram reduces the risk of stroke and other key outcomes such as death, dementia and cardiovascular disease. The programme comprises feasibility studies, a pilot trial, a randomised controlled trial, qualitative studies and an economic analysis. Recruitment and screening for the trial have been completed, and it is anticipated that follow-up will finish in 2027.
‡ The details of the SAFER Investigators are given in the [Supplementary Appendix] (available in the online version only).
Publication History
Received: 23 October 2025
Accepted after revision: 29 December 2025
Accepted Manuscript online:
15 January 2026
Article published online:
30 January 2026
© 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Davidson KW, Barry MJ, Mangione CM. et al; US Preventive Services Task Force. Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement. JAMA 2022; 327 (04) 360-367
- 2 Brandes A, Stavrakis S, Freedman B. et al. Consumer-led screening for atrial fibrillation: Frontier review of the AF-SCREEN International Collaboration. Circulation 2022; 146 (19) 1461-1474
- 3 Chao TF, Yeh YH, Chan YH. et al. The report of community-based and government-endorsed screening program of atrial fibrillation in Taiwan. Thromb Haemost 2024; 124 (01) 61-68
- 4 Mant J, Modi RN, Dymond A. et al; SAFER author group. Randomised controlled trial of population screening for atrial fibrillation in people aged 70 years and over to reduce stroke: Protocol for the SAFER trial. BMJ Open 2024; 14 (04) e082047
- 5 Svendsen JH, Diederichsen SZ, Højberg S. et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): A randomised controlled trial. Lancet 2021; 398 (10310): 1507-1516
- 6 McIntyre WF, Diederichsen SZ, Freedman B, Schnabel RB, Svennberg E, Healey JS. on behalf of the SCREEN-AF and AFFECT-EU Investigators. Screening for atrial fibrillation to prevent stroke: A meta-analysis. Eur Heart J Open 2022; 2 (04) oeac044
- 7 Mant J, Modi RN, Charlton P. et al. The feasibility of population screening for paroxysmal atrial fibrillation using hand-held electrocardiogram devices. Europace 2024; 26 (03) 1-9
- 8 Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): A multicentre, parallel group, unmasked, randomised controlled trial. Lancet 2021; 398 (10310): 1498-1506
- 9 Kemp Gudmundsdottir K, Svennberg E, Friberg L. et al. Randomised invitation to systematic NT-proBNP and ECG screening in 75 year olds to detect atrial fibrillation: STROKESTOP II. Circulation 2024; 150 (23) 1837-1846
- 10 Williams K, Modi RN, Dymond A. et al. Cluster randomised controlled trial of screening for atrial fibrillation in people aged 70 years and over to reduce stroke: Protocol for the pilot study for the SAFER trial. BMJ Open 2022; 12 (09) e065066
- 11 Powell A, Hoare S, Modi R. et al. How to embed qualitative research in trials: Insights from the feasibility study of the SAFER trial programme. Trials 2022; 23 (01) 394
- 12 Hoare S, Thomas GPA, Powell A, Armstrong N, Mant J, Burt J. Why do people choose not to take part in screening? Qualitative interview study of atrial fibrillation screening nonparticipation. Health Expect 2023; 26 (06) 2216-2227
- 13 Hoare S, Powell A, Modi RN. et al; SAFER Authorship Group. Why do people take part in atrial fibrillation screening? Qualitative interview study in English primary care. BMJ Open 2022; 12 (03) e051703
- 14 Modi RN, Massou E, Charlton PH. et al. Screening for atrial fibrillation with or without general practice involvement: A controlled study. BMC Prim Care 2025; 26 (01) 185
- 15 Hibbitt K, Brimicombe J, Cowie MR. et al. Reliability of single-lead electrocardiogram interpretation to detect atrial fibrillation: Insights from the SAFER feasibility study. Europace 2024; 26 (07) euae181
- 16 Prathivadi Bhayankaram K, Mant J, Brimicombe J, Dymond A, Williams K, Charlton PH. Telephone training to improve ECG quality in remote screening for atrial fibrillation. Physiol Meas 2024; 45 (12) 125005
- 17 Boskovic M, Jortveit J, Haraldsen MB. et al. The NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial: Rationale and design of a randomized controlled trial. Europace 2024; 26 (10) euae228
- 18 Lane DA, Andrade JG, Arbelo E. et al. Seminar on atrial fibrillation. Lancet 2026 ; In press
- 19 Lyth J, Svennberg E, Bernfort L. et al. Cost-effectiveness of population screening for atrial fibrillation: The STROKESTOP study. Eur Heart J 2023; 44 (03) 196-204
- 20 GOV.UK. Atrial fibrillation - UK National Screening Committee (UK NSC). Accessed October 8, 2025; available at: https://view-health-screening-recommendations.service.gov.uk/atrial-fibrillation/
- 21 Van Gelder ICV, Rienstra M, Bunting KV. et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024; 45 (36) 3314-3414
- 22 Chan N-Y, Orchard J, Agbayani M-J. et al. 2021 Asia Pacific Heart Rhythm Society (APHRS) practice guidance on atrial fibrillation screening. J Arrhythm 2021; 38 (01) 31-49
- 23 Lopes RD, Atlas SJ, Go AS. et al. Effect of screening for undiagnosed atrial fibrillation on stroke prevention. J Am Coll Cardiol 2024; 84 (21) 2073-2084
- 24 Wijjesurenda R, Pessoa-Amorim G, Buck G. et al. Remote screening for asymptomatic atrial fibrillation: The AMALFI Randomised Clinical Trial. JAMA 2025; 334: 1349-1357